Clinical Study

Methotrexate for the Treatment of Thyroid Eye Disease

Diego Strianese,1 Adriana Iuliano,1 Mariantonia Ferrara,1 Chiara Comune,1 Immacolata Baronissi,1 Pasquale Napolitano,1 Alessia D’Alessandro,1 Piergiacomo Grassi,1 Giulio Bonavolontà,1 Paola Bonavolontà,1 Antonio Sinisi,2 and Fausto Tranfa1

1 Department of Neuroscience, Odontostomatological and Reproductive Sciences, University “Federico II” of Naples, Via Pansini No. 5, 80131 Naples, Italy
2 Department of Endocrinology, Second University of Naples, Italy

Correspondence should be addressed to Fausto Tranfa; fausto.tranfa@unina.it

Received 12 August 2013; Revised 30 October 2013; Accepted 2 November 2013; Published 8 January 2014

Academic Editor: Torben Lykke Sørensen

Background/Aim. To evaluate the efficacy of methotrexate for the treatment of thyroid eye disease (TED). Methods. 36 consecutive patients with active TED, previously treated with corticosteroids but stopped due to the occurrence of side effects, were commenced on methotrexate therapy. Two different weekly doses were administered depending on the weight of the patient (7.5 mg or 10 mg). Clinical activity score (7-CAS), visual acuity (VA), ocular motility, exophthalmos, and eyelid position were retrospectively evaluated at 3, 6, and 12 months and compared with baseline data. Results. There was a statistically significant improvement in 7-CAS at 3, 6, and 12 months after treatment (P < 0.0001). There was no significant change in visual acuity. Ocular motility disturbances improved at 6 and 12 months (P < 0.001). There was no significant change in exophthalmos (mean 24 mm, SD 3 mm) or eyelid position (marginal reflex distance mean 6 mm, SD 1.5 mm) during the follow-up period. No side effects were registered. Conclusions. Methotrexate therapy is effective in reducing CAS and ocular motility disturbances. No significant improvement in proptosis or eyelid retraction should be expected from this treatment. Eventually, it might be considered a suitable alternative treatment in TED for patients who cannot tolerate steroids.

1. Introduction

Thyroid eye disease (TED) is an autoimmune disease involving the retroocular tissues associated with Graves’ disease [1, 2]. Typical signs and symptoms include proptosis, retroorbital pain, tearing, conjunctival redness and edema, corneal lesions, impaired extraocular motility with or without diplopia, periorbital edema, visual impairment, and, rarely, blindness.

Treatment options for TED include immunosuppressive agents, radiotherapy, and various surgical procedures such as orbital decompression, squint surgery, and correction of eyelid retraction [3–5]. Glucocorticoids are still the most widely used immunosuppressive agents for the treatment of TED and appear to be the most effective for associated soft tissue inflammation, optic neuropathy, and extraocular muscle impairment [6, 7]. The main disadvantages of glucocorticoid therapy are the potential recurrence of the disease after discontinuation and the side effects in long-term treatment [7]. Several alternative therapies have been proposed to manage resistant TED such as orbital radiation therapy, several other immunosuppressive agents, and biological drugs. However, the effectiveness of these treatments is still widely debated in the literature [8–15].

The aim of this study is to evaluate the efficacy of methotrexate used as single therapy in a group of patients with recurrence of the active TED after withdrawal of corticosteroids due to the onset of side-effects.

2. Materials and Methods

This is a retrospective comparative case series of 36 patients, from 2001 to 2010, who experienced reactivation of TED after withdrawal of corticosteroid therapy because of side-effects.
The study followed the Declaration of Helsinki on medical protocol and ethics.

Patients with sight threatening for compressive optic neuropathy were excluded from this study as they needed urgent treatment such as high-dose steroids or surgical decompression to prevent optic atrophy.

Before methotrexate therapy, all patients received as initial treatment intravenous pulse-methylprednisolone therapy at a dose of 10 mg/kg twice a week for 6 weeks (on Tuesdays and Thursdays), followed by oral prednisone at a dose of 30 mg/day, tapered to discontinuation over approximately 2 months. Patients with recurrence of inflammatory signs (7-point clinical activity score (7-CAS) ≥ 3 and in patients with asymmetric presentation the eye with the worse score was considered [16]) received as maintenance oral prednisone at a dose of 10 mg/day. From this group, 36 patients who stopped corticosteroids due to the occurrence of side-effects or intolerance to maintenance steroid therapy were commenced on methotrexate therapy. During a time period of 9 years, 36 patients received methotrexate as an alternative therapy to steroids. Reasons for cessation of steroid therapy included mood swings (25% of patients), hyperglycemia (21% of patients), hypertension (19% of patients), fecal blood (7% of patients), and complaining of puffiness, sleeplessness, facial flushing, slight tremor, and agitation (28% of patients).

Length of previous corticosteroid therapy ranged from 2 months to 1 year (median 5.12 months, Table 1). Time between onset of ocular symptoms and pulse therapy 5.12 months (2 m–1 y).

Patients with recurrence of inflammatory signs (7-CAS ≥ 3 defined active TED. Time from the onset of ocular symptoms to pulse steroid therapy 5.12 months (2 m–1 y).

2.2. Examination. The following parameters were measured at baseline (premethotrexate treatment) and at 3, 6, and 12 months after commencement of methotrexate treatment: 7-CAS [17, 18], ocular motility, exophthalmos, eyelid aperture, and visual acuity (VA). 7-CAS ≥ 3 defined active TED. Ocular motility was measured using the Light Reflex Method, recently validated for TED motility evaluation [19]: a score of 45° was given when the light's reflex was at the limbus, 30° at half way between the limbus and pupil edge and 15° at the pupil edge. Improvement in ocular motility was considered if variation was at least of 15°, as previously reported [19]. Exophthalmos was measured with Hertel exophthalmometry: a decrease of 2 mm was considered significant. Eyelid retraction was evaluated by measuring the Margin Reflex Distance (MRD). VA was measured with the Snellen Chart. Where different scores or measures of severity existed for the two separate eyes of one individual, scores of the worse eye were considered for analysis.

2.3. Statistical Analysis. Mean 7-CAS, exophthalmometry, and MRD measurements were compared before and after methotrexate treatment using Student's t-test. The chi squared test ($\chi^2$) was used to compare the results of VA and ocular motility data. MedCalc statistical software, version 11.3.0.0, was used for all statistical analyses. Only values of $P \leq 0.001$ were considered to be statistically significant.

3. Results

3.1. Outcome Parameters

3.1.1. 7-CAS. Mean 7-CAS score before methotrexate therapy was 4.05 (SD 1.11). There was a significant improvement in 7-CAS score at 3, 6, and 12 months ($P < 0.0001$) (Table 2). At 3 months, 24 patients (67%) had a reduction of 7-CAS in both eyes; at 6 months, 29 patients (80%) had a reduction of 7-CAS in both eyes; at 12 months, 34 patients (94%) had a reduction of 7-CAS in both eyes.

3.1.2. Visual Acuity (VA). Before methotrexate therapy, 18 patients (50%) had a VA of 20/20, 8 patients (22%) had 20/25, 8 patients (22%) had 20/30, and 2 patients (6%) had 20/50.
After 3 months there were no changes in VA. After 6 months, 2 patients had an improvement of one line on the Snellen Chart. After 12 months of followup only 1 patient had an improvement of three lines on the Snellen Chart. There were no significant improvements in VA with treatment.

3.1.3. Ocular Motility. 15 patients (42%) had some degree of gaze restriction at baseline. At 3 months, 4 patients improved (27% of patients with ocular motility disturbances), and at 6 and 12 months a total of 10 patients improved (67% of patients with ocular motility disturbances). The reduction of ocular motility restriction after 6 and 12 months of treatment was significant (P < 0.001) (Table 3).

3.1.4. Exophthalmos. Mean Hertel exophthalmometry measurement was 24 mm (range from 17 to 27, SD 3). There was no significant change at 3, 6, and 12 months after treatment (Table 3).

3.1.5. MRD. Mean MRD was 6 mm (range from 4 to 7, SD 1.5). There was no significant change at 3, 6, and 12 months after treatment (Table 3).

Methotrexate was well tolerated in all patients and no side effects were registered.

4. Discussion

The biological process of TED has originally been described by Rundle's curve [20]. The orbital disease usually starts with a dynamic period of active inflammation characterized by pain, redness, and swelling of the eyelids. During the active phase, disease severity increases and then plateaus. After this, disease severity slowly decreases until stable end stage, called inactive phase. Although the shape of the curve is representative of disease course for majority of patients, the time axis of Rundle's curve shows high individual variability: it can take from a few months to more than 5 years to reach the static phase. Prompt restoration of stable euthyroidism and immunosuppression may decrease the duration of the dynamic phase and reverse the tendency to progression.

Management of active inflammation in TED in the present study was based on the 7-CAS. When the inflammatory grade was 3 or greater, or if there was evidence of progression in the inflammation, immunosuppressive treatment was necessary. Systemic steroids are generally considered first-line treatment for TED as they can be given with systemic (oral or intravenous) or local (subconjunctival or retrobulbar) administration [5]. The efficacy of high-dose intravenous corticosteroid pulse therapy has been widely reported [6]. In our study all patients initially received corticosteroid pulse therapy, which is routinely used in our unit for patients with 7-CAS higher than 3. For those patients with persistent TED or reactivation after pulse therapy, long-term corticosteroid therapy is commonly used. However long-term use of corticosteroid can lead to complications such as high blood pressure, Cushing syndrome, diabetes, osteoporosis, fragility fractures, and in rare cases acute hepatitis [20]. Patients included in this study developed such side-effects over the treatment course, and when therapy was withdrawn, they experienced an increase in the inflammation score.

Many alternative therapies have been reported for such patients, although their efficacy is still under debate [12, 14, 15]. The efficacy of methotrexate has been reported for many autoimmune diseases requiring a long-term maintenance therapy such as rheumatoid arthritis, inflammatory bowel disease, and Wegener's granulomatosis [21]. Methotrexate is an immunosuppressive drug that inhibits dihydrofolate reductase enzyme, leading to the inhibition of the
DNA, RNA, and protein synthesis [15, 22]. Cytotoxic and antiproliferative effects can be seen at high doses, while anti-inflammatory and immunomodulatory effects can be observed with chronic low-dose treatment [23, 24]. The use of methotrexate is proposed on the basis of the autoimmune nature of TED [11, 15, 25, 26].

Patients who received methotrexate showed an early significant improvement of 7-CAS at 3, 6, and 12 months ($P < 0.0001$). Although none of patients included in this study had an optic neuropathy, VA improvement was reported but it was not significant. The improvement in ocular motility restriction was statistically significant after 6 and 12 months of methotrexate treatment ($P < 0.001$). Exophthalmometry and MRD measurements showed no statistically significant differences before and after treatment. Serious adverse effects were not reported in our study. However, side effects such as gastrointestinal disturbances, increased risk of opportunistic infections, bone marrow depression, interstitial pneumonitis, liver toxicity, asthenia, and fecal occult blood should always be considered since they have been reported in the literature [27, 28].

The addition of folate may reduce methotrexate toxicity, without affecting its effectiveness [14, 23]. The glucocorticoid-sparing effect of methotrexate is confirmed in our study, but this drug should not be used for more than 2 years in order to avoid the risk of megaloblastic anemia and lymphomas [22].

All the participants into this study had experienced recurrence of inflammatory signs of TED after withdrawal of corticosteroid treatment such as ocular pain and discomfort due to chemosis, hyperemia, and eyelid edema. These patients, as reported in previous studies, seem to have a phase of activity longer than usual [29]. Early surgical decompression could be considered for these patients even though its effectiveness needs to be confirmed [30]. In addition, patients with this condition may refuse surgery and methotrexate may be offered to them as a second-line therapy in order to contain the inflammatory process and prevent further complications due to fibrosis process. Hence, the indication for treatment with methotrexate should be a recurrent TED with 7-CAS $\geq$ 3 after withdrawal of steroids because of onset of steroid side-effects or intolerance.

Our study suggests that methotrexate therapy is useful for reducing the signs and symptoms of inflammation in TED, shortening the active phase, and reducing eye discomfort since all patients had a statistically significant reduction in inflammatory score. Methotrexate appears to be a suitable second-line treatment for patients with refractory TED to control the clinical profile and delay surgery until the disease stability.

**Authors’ Contribution**

D. Strianese designed the study. C. Comune, F. Tranfa, I. Baronissi, A. D’Alessandro, P. Grassi, M. Ferrara, P. Bonavolontà conducted the study. D. Strianese and M. Ferrara performed the collection, management, analysis, and interpretation of data. C. Comune, A. Iuliano, I. Baronissi, P. Grassi, A. D’Alessandro, M. Ferrara, A. Sinisi, F. Tranfa, G. Bonavolontà prepared, reviewed, or approved the paper.

**Conflict of Interests**

The authors declare that they have no conflict of interests.

**References**

[1] R. S. Bahn, “Graves’ ophthalmopathy,” *The New England Journal of Medicine*, vol. 362, no. 8, pp. 726–774, 2010.

[2] M. Comerci, A. Elefante, D. Strianese et al., “Semi-automatic regional segmentation to measure orbital fat volumes in thyroid-associated ophthalmopathy. Validation study,” *The Neuroradiology Journal*, vol. 26, no. 4, pp. 373–379, 2013.

[3] G. Uccello, P. Vassallo, D. Strianese, and G. Bonavolonta, “Free levator complex recession in Graves’ ophthalmopathy. Our experience,” *Orbit*, vol. 13, no. 3, pp. 119–123, 1994.

[4] H. Koshiyama, T. Koh, K. Fujiwara, K. Hayakawa, S.-I. Shimbo, and T. Misaki, “Therapy of Graves’ ophthalmopathy with intravenous high-dose steroid followed by orbital irradiation,” *Thyroid*, vol. 4, no. 4, pp. 409–413, 1994.

[5] W. M. Wiersinga and M. F. Prummel, “Graves’ ophthalmopathy: a rational approach to treatment,” *Trends in Endocrinology and Metabolism*, vol. 13, no. 7, pp. 280–287, 2002.

[6] L. Bartalena, C. Marroccoli, M. Tanda, and A. Pinchera, “Management of thyroid eye disease,” *European Journal of Nuclear Medicine*, vol. 29, no. 2, pp. S458–S465, 2002.

[7] G. E. Krassas and A. E. Heufelder, “Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts,” *European Journal of Endocrinology*, vol. 144, no. 4, pp. 311–318, 2001.

[8] C. Marroccoli, G. J. Kahaly, G. E. Krassas et al., “Selenium and the course of mild Graves’ orbitopathy,” *European Journal of Nuclear Medicine*, vol. 36, no. 20, pp. 1920–1931, 2001.

[9] M. P. Mourits, M. L. Van Kempen-Harteveld, M. B. García García, H. P. Koppeschaar, L. Tick, and C. B. ter Wee, “Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study,” *The Lancet*, vol. 355, no. 9214, pp. 1505–1509, 2000.

[10] N. Minakara and D. G. Ezra, “Rituximab for thyroid-associated ophthalmopathy,” *Cochrane Database of Systematic Reviews*, vol. 5, Article ID CD009226, 2013.

[11] P. Sanyal, R. G. Binger, and L. E. Braverman, “Use of methotrexate to treat isolated graves ophthalmopathy developing years after thyroidectomy and iodine 131 treatment of papillary thyroid cancer,” *Endocrine Practice*, vol. 14, no. 4, pp. 422–425, 2008.

[12] L. Bartalena, C. Marroccoli, M. L. Tanda et al., “Orbital radiotherapy for Graves’ ophthalmopathy,” *Thyroid*, vol. 12, no. 3, pp. 245–250, 2002.

[13] M. F. Prummel, A. Berghout, W. M. Wiersinga, M. P. Mourits, L. Koornneef, and L. Blank, “Randomised double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy,” *The Lancet*, vol. 342, no. 8877, pp. 949–954, 1993.

[14] H. Smith and J. T. Rosenbaum, “A role for methotrexate in the management of non-infectious orbital inflammatory disease,” *British Journal of Ophthalmology*, vol. 85, no. 10, pp. 1220–1224, 2001.

[15] L. Bartalena, M. L. Tanda, A. Meade et al., “Novel approaches to the management of Graves’ ophthalmopathy,” *Hormones*, vol. 1, no. 2, pp. 76–90, 2002.
D. Strianese, R. Piscopo, and A. Elefante, “Unilateral proptosis in thyroid eye disease with subsequent contralateral involvement: retrospective follow-up study,” *BMC Ophthalmology*, vol. 13, p. 21, 2013.

M. P. Mourits, M. F. Prummel, W. M. Wiersinga, and L. Koornneef, “Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy,” *Clinical Endocrinology*, vol. 47, no. 1, pp. 9–14, 1997.

A. Pinchera, W. Wiersinga, D. Gliener et al., “Classification of eye changes of Graves’ disease,” *Thyroid*, vol. 2, no. 3, pp. 235–236, 1992.

P. J. Dolman, K. Cahill, C. N. Czyz et al., “Reliability of estimating ductions in thyroid eye disease: an international thyroid eye disease society multicenter study,” *Ophthalmology*, vol. 119, no. 2, pp. 382–389, 2012.

F. F. Rundie, “Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy,” *Clinical Science*, vol. 5, pp. 177–194, 1945.

N. Songsiridej and D. E. Furst, “Methotrexate—the rapidly acting drug,” *Bailliere's Clinical Rheumatology*, vol. 4, no. 3, pp. 575–593, 1990.

R. Le Moli, L. Baldeschi, P. Saeed, N. Regensburg, M. P. Mourits, and W. M. Wiersinga, “Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves’ ophthalmopathy,” *Thyroid*, vol. 17, no. 4, pp. 357–362, 2007.

M. Seitz, “Molecular and cellular effects of methotrexate,” *Current Opinion in Rheumatology*, vol. 11, no. 3, pp. 226–232, 1999.

D. S. Rampton, “Methotrexate in Crohn’s disease,” *Gut*, vol. 48, no. 6, pp. 790–791, 2001.

L. Bartalena, A. Pinchera, and C. Marcocci, “Management of Graves’ ophthalmopathy: reality and perspectives,” *Endocrine Reviews*, vol. 21, no. 2, pp. 168–199, 2000.

G. S. Alarcón, J. M. Kremer, M. Macaluso et al., “Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study,” *Annals of Internal Medicine*, vol. 127, no. 5, pp. 356–364, 1997.

N. D’Andrea, L. Triolo, G. Margagnoni, A. Aratari, and C. M. Sanguinetti, “Methotrexate-induced pneumonitis in Crohn’s disease: case report and review of the literature,” *Multidisciplinary Respiratory Medicine*, vol. 5, no. 5, pp. 312–319, 2010.

H. Amital, Y. Aronson, G. Chodick, and V. Shalev, “Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate,” *Rheumatology*, vol. 48, no. 9, pp. 1107–1110, 2009.

F. Menconi, M. A. Profilo, M. Leo et al., “Spontaneous improvement of untreated mild Graves’ ophthalmopathy: the Rundle curve revisited,” *Thyroid*, 2013.

L. Baldeschi, K. Macandie, E. Koetsier, L. E. C. M. Blank, and W. M. Wiersinga, “The influence of previous orbital irradiation on the outcome of rehabilitative decompression surgery in graves orbitopathy,” *American Journal of Ophthalmology*, vol. 145, no. 3, pp. 534–540, 2008.